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   Schizophrenia  is  a  chronic  mental  disorder  affecting  millions  worldwide.  It  has  no  
known  cure.  Current  pharmaceutical  treatments  have  shown  efficacy  in  only  one  of  the  
three  symptom  clusters  of  schizophrenia,  providing   little  or  no  benefit   in   the  other   two.  
Furthermore,  the  current  standard-­of-­care  drugs,  known  as  atypical  antipsychotics,  carry  
risks   of   severe   side   effects   affecting   multiple   body   systems.   Most   patients   opt   to  
discontinue   drug   therapy   within   two   years   of   initiation   due   to   lack   of   efficacy   and/or  
preponderance  of  adverse  effects.  Previous  findings  have  shown  that  chronic  usage  of  
atypical  antipsychotics  causes  a  5-­HT2A-­dependent  upregulation  of  histone  deacetylase  
2  (HDAC2),  which  in  turn  leads  to  downregulation  of  metabotropic  glutamate  receptor  2  
(mGluR2),  a  G  protein-­coupled  receptor  with  an  important  role  in  synaptic  plasticity.  The  
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present   study   aims   to   characterize   the   extent   to   which   this   downregulation   leads   to  
specific   functional  outcomes,  and   in  doing  so,  may  help   identify  new   targets   for  more  





Chapter  1:  Introduction  
  
1.1:  Schizophrenia  and  its  Treatment  
  
   Schizophrenia  is  a  chronic,  severe,  and  debilitating  mental  disorder  that  impacts  
how  a  person  thinks,  feels,  and  behaves.1  The  disorder  carries  considerable  societal  
costs2  and  afflicts  approximately  1%  of  the  world’s  population.3  Symptoms  most  often  
appear  in  late  adolescence  and  early  adulthood,  and  are  grouped  into  three  main  
classes:  positive  symptoms  (e.g.  hallucinations,  delusions),  negative  symptoms  (e.g.  
flattened  affect,  anhedonia),  and  cognitive  deficits  (e.g.  poor  executive  function,  
problems  with  working  memory).1  Despite  the  fact  that  the  precise  causes  of  the  
disorder  remain  unknown,  there  is  a  consensus  that  schizophrenia  is  multifactorial  in  
origin,  arising  from  interactions  between  genetic,  environmental,  psychological,  and  
social  factors.4    
Pharmacological  treatment  for  schizophrenia  consists  primarily  of  a  class  of  
drugs  known  as  antipsychotics.  While  effective  against  positive  symptoms  of  the  
disorder  in  30-­40%  of  patients,5  antipsychotics  provide  limited,  if  any,  relief  from  the  
negative  and  cognitive  symptoms,6  which  are  predictors  of  functional  disability.7  
Persons  with  schizophrenia  have  only  a  5-­10%  chance  of  making  a  full  recovery  
regardless  of  antipsychotic  use.5  In  addition  to  these  considerable  shortcomings,  
antipsychotics  also  carry  a  vast  array  of  side  effects,  some  of  which  are  severe.  
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Consequently,  rates  of  non-­adherence  to  medication  are  high  in  this  population  –  as  
many  as  75%  of  patients  stop  treatment  within  two  years  of  initiating  therapy.8  Without  
doubts,  treatment  of  schizophrenia  is  an  area  where  current  clinical  needs  remain  
woefully  unmet.  
The  extent  of  this  problem  is  perhaps  best  illustrated  by  the  story  of  the  
antipsychotic  drug  clozapine,  which  was  developed  in  the  1960s.  Today,  over  half  of  a  
century  later,  it  remains  the  only  drug  proven  to  be  effective  for  treatment-­resistant  
schizophrenia.8  Despite  a  lowered  incidence  of  extrapyramidal  motor  symptoms,  
clozapine  still  carries  risk  for  many  adverse  effects,9  with  risks  of  agranulocytosis,  
considerable  weight  gain,  diabetes,  metabolic  syndrome,  bowel  obstruction,  and  other  
serious  problems.10  Dishearteningly,  in  the  many  years  since  the  development  of  
clozapine,  all  attempts  to  create  a  compound  that  retains  its  unmatched  efficacy  –  yet  
sheds  its  many  adverse  effects  –  have  failed.    
  
1.2:  Typical  Antipsychotics  
  
The  earliest  hypotheses  of  schizophrenia  emerged  from  the  discovery  of  the  
antipsychotic  action  of  chlorpromazine  and  the  later  characterization  of  its  target,  the  
dopamine  D2  receptor  (DRD2).  The  foundation  of  the  dopamine  hypothesis  of  
schizophrenia  can  be  traced  back  to  the  1970s,  when  reports  that  the  known  
antipsychotic  drugs  were  antagonists  at  DRD2  and  that  clinical  efficacy  of  these  drugs  
was  strongly  correlated  to  their  affinity  for  the  striatal  DRD2.  Further  support  for  this  
hypothesis  was  derived  from  observations  that  high  amounts  of  amphetamine,  a  
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dopamine  transporter  substrate,  can  induce  psychotic  symptoms,  as  well  as  reports  that  
reserpine,  a  drug  that  depletes  monoamine  neurotransmitter  levels  in  synapses,    was  
capable  of  reducing  such  symptoms.8  Until  recently,  the  prevailing  notion  was  that  
dysfunctional  dopaminergic  activity  in  forebrain  regions  was  largely  responsible  for  
schizophrenia.11  The  earlier  antipsychotic  drugs  (e.g.  chlorpromazine,  haloperidol),  now  
referred  to  as  “typical  antipsychotics,”  are  potent  DRD2  antagonists,  though  they  exert  
additional  effects  on  a  variety  of  targets.  These  drugs  have  a  high  incidence  of  
extrapyramidal  motor  side  effects,  such  as  tardive  dyskinesia,  which  complicates  their  
use.    
  
1.3:  Atypical  Antipsychotics  
  
More  recently,  research  regarding  the  molecular  underpinnings  of  schizophrenia  
has  focused  on  other  neurotransmission  systems,  such  as  serotonin  and  glutamate.  
Whereas  the  typical  antipsychotic  drugs  are  DRD2  antagonists,  newer  drugs  also  
exhibit  potent  antagonism  at  the  serotonin  receptor  2A  (5-­HT2A),  generally  in  addition  to  
slightly  lowered  affinity  for  DRD2.  These  drugs,  referred  to  as  “atypical”  antipsychotics,  
have  now  become  first-­line  treatments  for  patients  with  schizophrenia.12  Compounds  in  
this  class  include  clozapine,  risperidone,  and  olanzapine.  Their  main  advantage  over  
the  older,  typical  antipsychotics  is  a  lowered  incidence  of  extrapyramidal  motor  side  
effects.  However,  as  previously  mentioned,  the  atypical  medications  are  not  without  
their  own  risk  of  serious  adverse  effects,  and  only  address  certain  symptoms.  Drugs  for  
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schizophrenia  are  in  need  of  improvement,  but  additional  information  on  mechanism(s)  
of  the  disorder  is  required  to  guide  new  drug  development.    
  
1.4:  Glutamatergic  Dysfunction  and  New  Drug  Development  
  
Recent  discoveries  concerning  glutamatergic  dysfunction  in  schizophrenia  have  
buttressed  attempts  to  develop  a  newer  class  of  antipsychotic  drugs.  Efforts  in  this  area  
in  particular  were  made  by  Eli  Lilly  &  Co.,  who  created  and  incrementally  improved  a  
novel  class  of  compounds  –  the  group  II  metabotropic  glutamate  receptor  agonists  –  
that  showed  promise  for  antipsychotic  utility,  culminating  in  LY2140023  (pomaglumetad  
methionil).  While  preclinical13  and  early  clinical14  studies  were  encouraging  in  this  
regard,  ensuing  clinical  trials15-­18  were  not,  as  they  failed  to  demonstrate  efficacy  of  
LY2140023  in  treatment  of  schizophrenia.  Ultimately,  Lilly  abandoned  phase  III  
development  in  2012.19    
During  the  past  six  years,  new  research  findings20-­22  have  revealed  more  
information  about  how  metabotropic  glutamate  receptor  2  (mGluR2),  one  of  the  targets  
of  the  Lilly-­developed  agonists,  is  regulated.  In  elucidating  the  nature  of  the  mechanism  
that  underlies  this  regulation  as  well  as  its  functional  consequences,  these  works,  in  
conjunction  with  the  present  study,  might  offer  a  possible  explanation  as  to  why  the  
newer  drug  was  only  effective  in  the  patient  population  used  in  the  earliest  clinical  study,  
and  not  in  other  patients.  In  the  years  since  the  trials’  completion,  multiple  authors23,24  
have  raised  the  concern  that  patient  selection,  which  was  done  without  knowledge  of  
how  prior  treatment  with  atypical  antipsychotics  might  affect  the  potential  of  newer  
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drugs,  could  be  at  least  partially  responsible  for  the  new  drug’s  failure  to  show  efficacy  
in  later  trials.  Progress  in  this  area  will  further  enrich  knowledge  of  schizophrenia  and  its  
treatment  at  the  molecular  level,  thereby  aiding  in  attempts  to  develop  new  and  
improved  treatment  strategies,  an  urgent  clinical  need.  
  
1.5:  G  Protein-­Coupled  Receptors  
  
G  protein-­coupled  receptors  (GPCRs)  are  a  large  and  diverse  family  of  integral  
membrane  proteins  found  in  eukaryotes.  GPCRs  achieve  signal  transduction  across  
membrane  barriers  by  coupling  extracellular  ligand  binding  to  the  initiation  of    
intracellular  signaling  cascades.  Their  structure  is  well-­suited  to  carry  out  this  function,  
consisting  of  an  extracellular  N-­terminus,  an  intracellular  C-­terminus,  and  seven  
transmembrane  domains  that  are  held  together  by  both  intra-­  and  extracellular  loops  
(Fig.  1).  Intracellular  portions  of  the  GPCR  are  responsible  for  coupling  to  heterotrimeric  
G  proteins,  consisting  of  α,  β,  and  γ  subunits  (Fig.  1).  In  response  to  ligand  binding  
events  occurring  on  the  extracellular  aspect  of  the  GPCR,  the  G  protein  undergoes  a  
conformational  change  and  becomes  activated.  As  a  result,  it  initiates  intracellular  
signaling  pathways  that  can  regulate  a  wide  array  of  downstream  effector  molecules  
(e.g.  ion  channels,  enzymes,  and  transcription  factors),  ultimately  leading  to  a  biological  
response  (Fig.  1).  There  are  multiple  classes  of  GPCRs,  and  members  of  different  
classes  exhibit  some  differences  in  structure  and  function.  Class  C  GPCRs,  such  as  the  
metabotropic  glutamate  receptors,  contain  the  ligand-­binding  site  within  the  extracellular  




Figure  1.  General  structure  and  scheme  of  GPCRs.  Ligands  (i.e.  biogenic  amines,  amino  acids,  ions,  
lipids,  peptides,  proteins,  etc.)  bind  to  extracellular  portions  of  the  GPCR  as  a  means  to  reach  targets  on  
the  intracellular  side  of  the  membrane,  in  the  cytoplasm,  and  in  the  nucleus.  The  GPCR  is  coupled  to  
heterotrimeric  G  proteins,  which  are  made  up  of  the  subunits  α,  β,  and  γ.  Upon  activation  by  a  ligand,  the  
receptor  undergoes  a  conformational  change  that  results  in  the  replacement  of  GDP  bound  to  the  α  
subunit  with  GTP,  causing  the  α  subunit  to  dissociate  from  the  other  subunits.  There  are  four  families  of  
Gα  subunits,  each  of  which  are  associated  with  distinct  signaling  cascades.  Functional  activation  of  the  
GPCR  has  many  important  regulatory  functions  in  an  array  of  intracellular  signaling  networks.  As  such,  
disruption  of  normal  functional  activation  can  have  far-­reaching  implications  for  the  cell.  Image  source:  










1.6:  Histone  Deacetylases     
  
Histone  deacetylases  (HDACs)  are  widely-­expressed  enzymes  that  perform  
important  epigenetic  regulatory  functions.  Generally,  HDACs  deacetylate  (i.e.  catalyze  
the  removal  of  an  acetyl  group  from)  lysine  residues  on  histones.  This  alters  the  
conformation  of  the  histone  N-­terminal  tails,  which  has  the  ultimate  consequence  of  
pulling  the  histones  and  their  wound  DNA  more  tightly  together  into  an  increasingly  
condensed  state.  Less-­accessible  chromatin  correlates  with  reduced  transcription  
and/or  silencing  of  genes.  (Fig.  2)  Conversely,  chromatin  is  rendered  more  “open”  to  
transcriptional  machinery  by  the  opposing  process  of  acetylation,  performed  by  histone  
acetyltransferases.  Normally,  there  is  a  carefully-­controlled  balance  between  
deacetylation  and  acetylation,  but  this  balance  can  be  perturbed  by  numerous  insults  
such  as  stress  and  disease  (Fig.  2).  Resultant  dysregulation  of  transcription  can  lead  to  
a  variety  of  outcomes  depending  on  what  genes  are  affected.  In  neurons,  normal  
expression  of  many  genes  related  to  synaptic  plasticity  is  compromised  by  excessive  
HDAC2  activity.  Drugs  that  inhibit  HDACs  may  be  able  to  restore  a  normal  balance  
between  transcriptional  activation  and  lack  thereof  (Fig.  2),  and  are  currently  being  




Figure  2.  The  opposing  processes  of  histone  acetylation  and  deacetylation.  Shown  here  in  a  
neuron,  maintenance  of  the  balance  between  histone  acetylation  and  deacetylation  is  critical  to  ensure  
proper  regulation  of  transcription  in  the  cell.  When  this  balance  is  disrupted,  the  cell  is  less  able  to  control  
transcription  of  many  genes  important  in  cognitive  function,  synaptic  plasticity,  and  mood  state.  HDAC  
inhibitors  can  be  used  to  try  and  rectify  imbalances  resulting  from  excessive  deacetylation  of  histones.  
Image  source:  Abel  and  Zukin,  2008.27  Reproduced  with  permission.  
While  multiple  HDACs  exist,  Histone  deacetylase  2  (HDAC2)  is  of  particular  
importance  in  the  context  of  schizophrenia.  Briefly,  it  has  repeatedly  been  shown20,28  
that  chronic  treatment  with  atypical  antipsychotics  (e.g.  risperidone,  clozapine)  causes  
an  epigenetically-­mediated  downregulation  of  mGluR2  in  the  human  and  mouse  frontal  
cortex  in  a  5-­HT2A-­dependent  manner,  and  that  HDAC2  is  a  main  effector  in  this  
process.    
  
1.7:  Rationale  for  This  Study  
  
As  mentioned  earlier,  mGluR2  is  a  G  protein-­coupled  receptor  (GPCR),  a  class  
of  proteins  that  accomplish  signal  transduction  across  a  cellular  membrane  by  coupling  
cell  surface  receptor  binding  with  intracellular  activation  of  a  signaling  cascade.  This  
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characteristic  makes  mGluR2  amenable  to  certain  modes  of  study.  One  way  to  gauge  
the  extent  to  which  mGluR2  downregulation  by  HDAC2  translates  into  functional  
outcomes  is  to  measure  the  level  to  which  mGluR2  couples  extracellular  ligand  binding  
to  initiation  of  intracellular  signaling  cascade  (i.e.  functional  activation).  This  can  be  
achieved  in  mouse  brain  samples  by  stimulating  the  mGlu2  receptors  in  the  presence  of  
a  hydrolysis-­resistant  radiolabeled  nucleotide  that  participates  in  the  process  of  GPCR  
signal  transduction.    
While  chronic  clozapine  treatment  is  known  to  decrease  expression  of  mGluR2  in  
the  frontal  cortex  via  HDAC2  in  a  5-­HT2A-­dependent  manner,  the  extent  to  which  this  
action  affects  the  function  of  mGluR2  has  not  been  characterized.  For  this  reason,  the  
current  study  aims  to  assess  the  specific  contribution  of  HDAC2  to  loss  of  function  of  
mGluR2  at  the  level  of  its  G  protein.  As  such,  mice  were  treated  chronically  with  
clozapine  in  order  to  induce  the  HDAC2-­mediated  downregulation  of  mGluR2.  Half  of  
the  mice  had  conditional  knockouts  of  HDAC2  in  cortical  pyramidal  neurons,  whereas  
the  other  half  had  natively  functional  HDAC2  in  those  neurons.  Upon  completion  of  
treatment,  frontal  cortex  brain  samples  were  assessed  on  the  basis  of  functional  
activation  by  agonist-­stimulated  [35S]GTPγS  binding  assay,  and  results  compared  










Chapter  2:  Background  
  
2.1:  Chlorpromazine  and  the  Dopamine  Hypothesis  of  Schizophrenia  
  
   The  earliest  ideas  about  the  underlying  mechanisms  of  schizophrenia  can  be  
traced  back  to  the  development  of  the  
phenothiazine  derivative  
chlorpromazine  (Fig.  3)  in  the  1950s.  
A  few  years  prior,  in  the  late  1940s,  
French  scientists  at  Rhône-­Poulenc  
laboratories  were  investigating  a  
series  of  substituted  phenothiazine  
derivatives  for  many  effects,  one  of  
which  was  antihistaminergic  activity.  
These  efforts  led  to  the  discovery  of  
two  closely-­related  and  historically  
important  drugs:  1)  promethazine,  a  
potent  antihistamine  that  is  still  
widely  used  today,  and  2)  










Figure   3.   Phenothiazine   and   chlorpromazine.  
Chemical   structures   of   phenothiazine   (a)   and   its  
derivative   chlorpromazine   (b)   are   shown.   Structure  




antihistamine  whose  additional  characteristics,  once  found,  would  rapidly  change  the  
field  of  clinical  psychiatry  forever.29    
In  1951,  while  attempting  to  harness  the  sedative  effects  of  promethazine  and  
chlorpromazine  for  use  as  surgical  anesthetics,  French  surgeon  Henri  Laborit  observed  
that  patients  given  chlorpromazine  before  surgery  not  only  became  sedated  but  also  
displayed  much  less  anxiety.29,30  Believing  that  these  effects  might  be  useful  in  a  
psychiatric  setting,  Laborit  gave  the  compound  to  psychiatrists  working  in  psychiatric  
facilities  in  Paris,29  where  it  was  soon  found  to  reduce  symptoms  of  psychosis  in  a  1952  
trial.31  Later  that  year,  Rhône-­Poulenc  approached  three  American  pharmaceutical  
companies  about  the  possibility  of  a  licensing  agreement  to  market  chlorpromazine  in  
the  United  States.  After  being  turned  down  twice,    Rhône-­Poulenc  reached  a  licensing  
agreement  with  U.S.  company  Smith,  Kline  &  French  (SK&F)  in  1952.  Extensive  testing  
was  performed,  and  by  1954,  SK&F  was  marketing  chlorpromazine  as  Thorazine  in  the  
United  States.32    
The  introduction  of  chlorpromazine  had  a  profound  effect  on  the  practice  of  
clinical  psychiatry  in  the  United  States.  Until  that  time,  American  psychiatrists  were  not  
using  drugs  to  treat  mental  illness.  Instead,  they  relied  almost  exclusively  on  shock  
therapies  and/or  various  forms  of  psychotherapy.33  When  chlorpromazine  began  to  be  
used  in  treatment  facilities  such  as  the  VA  neuropsychiatric  hospital  system,  treatment  
practices  overall  changed  rapidly.  There  is  an  inverse  correlation  between  the  adoption  
of  drugs  like  chlorpromazine  in  VA  neuropsychiatric  facilities  and  the  usage  of  
electroconvulsive  and  insulin  shock  therapy  in  those  facilities.33  While  this  trend  is  
certainly  noteworthy,  it  cannot  be  concluded  that  drugs  alone  were  responsible  for  it.  
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However,  what  can  be  said  with  certainty  is  that  the  introduction  of  drugs  like  
chlorpromazine  was  a  hallmark  event  in  the  history  of  schizophrenia.  Dr.  Douglas  
Goldman,  one  of  the  first  to  conduct  a  trial  with  chlorpromazine  for  schizophrenia  in  the  
United  States,  said  the  following  at  a  conference  in  1955:  “chronic,  severe  
schizophrenic  illness,  resistant  to  all  other  treatments,  …  has  represented  a  ‘therapeutic  
no  man’s  land’  …  The  application  of  chlorpromazine  in  such  situations  has,  however,  
accomplished  results  never  heretofore  achieved.”33    
At  that  time,  psychiatrists  had  no  concept  of  the  molecular  workings  of  the  
nervous  system  and  brain,  but  the  clear  benefits  conferred  by  drugs  no  doubt  stimulated  
the  curiosity  of  scientists  and  psychiatrists  alike,  ushering  in  a  new  paradigm  where  
investigators  sought  to  understand  how  small  molecules  could  affect  behavior.  This  
knowledge  could  lead  to  better  understanding  of  the  underlying  causes  of  a  vast  array  
of  mental  disorders,  thereby  serving  as  a  foundation  for  development  of  new  and  
effective  treatments.  In  this  way,  deployment  of  chlorpromazine  and  similar  drugs  for  
treatment  of  the  mentally  ill  marks  the  origin  of  modern  biological  psychiatry.  When  the  
dopaminergic  antipsychotic  chlorpromazine  was  introduced,  the  neurotransmitter  
dopamine  had  not  yet  been  discovered,  and  it  would  be  over  twenty  years  before  the  
main  target  receptor  of  the  drug  was  conclusively  elucidated  in  the  mid-­1970s  (as  
reviewed  by  Howes  and  Kapur34  as  well  as  by  Madras35).  Today,  this  target  is  known  as  
the  dopamine  D2  receptor.    
Characterization  of  the  role  of  dopamine  receptors  in  antipsychotic  effect  remains  
one  of  the  most  important  events  in  the  development  of  dopaminergic  hypotheses  of  
schizophrenia.  In  1975,  Seeman  and  Lee  reported  a  direct  relationship  between  the  
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clinical  effectiveness  of  antipsychotic  drugs  and  their  ability  to  block  dopamine  
receptors.36  In  keeping  with  this  finding,  the  idea  that  schizophrenia  resulted  from  
altered  dopamine  receptor  density  in  general  (as  reviewed  by  Howes,  McCutcheon,  and  
Stone)37  became  the  most  prevalent  of  the  time.  While  many  refinements  to  the  
understanding  of  dopamine’s  involvement  in  schizophrenia  have  occurred  since  then,  it  
is  worth  noting  that  all  currently  approved  drugs  for  schizophrenia  are  alike  in  that  they  
share  an  affinity  for  the  dopamine  D2  receptor.38    
Until  recently,  the  idea  that  excessive  dopaminergic  transmission  in  regions  of  
the  forebrain  is  a  major  factor  underlying  schizophrenia  has  been  the  basis  of  prevailing  
hypotheses  concerning  the  pathophysiology  of  disorder.  However,  drugs  that  target  this  
dopaminergic  transmission  have  only  exhibited  limited  efficacy  and  carry  risks  of  many  
severe  side  effects,  as  previously  mentioned.  These  issues  have  driven  researchers  to  
identify  and  characterize  dysfunction  in  additional  neurotransmission  systems  (i.e.  
glutamate,  serotonin)  in  an  effort  to  develop  improved  treatments  for  schizophrenia.11  
  
2.2:  Glutamatergic  Hypotheses:  The  NMDAR  Antagonism  Model  
  
   In  the  same  way  that  search  for  the  mechanism  of  action  of  known  antipsychotic  
compounds  led  to  the  eventual  discovery  of  the  dopamine  D2  receptor  (DRD2)  and  the  
dopaminergic  hypothesis  of  schizophrenia,  efforts  to  understand  how  seemingly  pro-­
psychotic  compounds  created  their  effects  formed  the  basis  of  glutamatergic  
hypotheses  in  schizophrenia.  Early  observations  that  1)  administration  of  phencyclidine  
(PCP)  to  normal  subjects  caused  schizophrenia-­like  symptoms  belonging  to  all  three  
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symptom  clusters  (i.e.  positive,  negative,  and  cognitive)  and  2)    that  PCP,  when  given  to  
chronic  schizophrenia  patients,  seemed  to  worsen  their  symptoms  as  if  they  had  re-­
entered  the  acute  phase,  originally  spurred  interest  in  this  direction.39  Other  compounds  
like  ketamine  have  also  been  found  to  induce  this  phenomenon.40  Both  PCP  and  
ketamine  are  members  of  the  same  chemical  class  (arylcyclohexylamines),  and  both  
possess  ability  to  antagonize  the  N-­methyl-­D-­aspartate  receptor  (NMDA  receptor),  an  
ionotropic  glutamate  receptor  in  nerve  cells.  Notably,  it  has  been  demonstrated  that  the  
ability  of  NMDAR  blockade  to  produce  symptoms  relevant  to  schizophrenia  (e.g.  
hyperlocomotion  in  rodents)  remains  present:  1)  in  the  absence  of  dopaminergic  activity  
and/or  2)  in  the  presence  of  dopamine  antagonism.41  In  light  of  these  findings,  
researchers  realized  that  glutamatergic  dysfunction  in  the  context  of  schizophrenia  
warranted  further  investigation.    
   In  1995,  Moghaddam  and  Liu  reported  on  findings  that  administration  of  NMDAR  
antagonists  to  awake,  freely-­moving  rats  increased  glutamate  efflux  in  the  hippocampus  
and  striatum  in  a  dose-­dependent  manner.42  These  findings  were  extended  to  the  
prefrontal  cortex  (PFC)  two  years  later,  when  further  evidence  demonstrated  that  
subanesthetic  doses  of  ketamine  (i.e.  enough  to  produce  cognitive  impairment  and  
other  symptoms  relevant  to  schizophrenia,  but  not  enough  to  render  the  animal  
unconscious)  increase  glutamate  efflux  in  the  PFC,  thereby  disturbing  normal  
dopaminergic  neurotransmission  and  creating  cognitive  deficits.43  This  alteration  to  
normal  dopaminergic  function  in  the  PFC  was  partially  reversed  by  the  administration  of  
AMPA  receptor  antagonists,  suggesting  that  AMPA  receptors  might  occupy  an  
intermediary  position  in  the  mechanism.43    
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This  hypothetical  pathway  was  supported  and  perhaps  further  explained  by  
findings  that  NMDAR  antagonists  increased  the  spontaneous  activity  of  cortical  
neurons.  However,  this  increased  activity  was  marked  not  by  increased  firing  of  already-­
present  coordinated  burst  potentials,  but  instead  by  an  increase  in  randomly  distributed  
single-­spike  potentials.44  Authors  have  described  these  randomly  distributed  spikes  as  
“noise”  that  diminishes  the  ability  of  cortical  neurons  to  filter  out  irrelevant  
information,6,45  which  ultimately  leads  to  expression  of  abnormal  behavior  –  as  
demonstrated  in  rats  whose  display  of  behavioral  stereotypy  “correlates  with  increases  
in  random  spike  activity.”44  While  it  is  not  realistic  to  expect  any  animal  model  to  mimic  
all  aspects  of  complex  mental  disorders  such  as  schizophrenia,  in  the  case  of  cognitive  
deficit,  the  NMDAR  antagonism  model  possesses  both  face  and  construct  validity.44  In  
short,  the  model’s  face  validity  stems  from  its  ability  to  recapitulate  PFC-­dependent  
cognitive  impairments  similar  to  those  seen  in  schizophrenia  (as  detailed  by  
Moghaddam  &  Jackson46);;  the  model’s  construct  validity  is  afforded  by  data  from  
postmortem  brain47-­49  as  well  as  genome-­wide  association  studies50  implicating  
irregularities  in  NMDAR  function  among  persons  with  schizophrenia.  
     
2.3:  Emergence  of  mGluR2/3  Agonism  as  a  Treatment  Strategy  
  
   Based  on  the  idea  of  NMDAR  hypofunction  being  responsible  for  cortical  
glutamatergic  hyperfunction  as  it  relates  to  schizophrenia,  a  first  mode  of  approach  to  
remedy  this  dysfunction  might  be  to  target  NMDARs  directly,  for  example  by  orthosteric  
agonists.  However,  this  strategy  is  not  viable  because  orthosteric  agonism  of  NMDAR  
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can  cause  several  detrimental  effects  (e.g.  seizures  and  excitotoxicity).51  Attempts  to  
target  other  sites  on  the  NMDAR  receptor  with  positive  allosteric  modulators  (PAMs)  
have  been  made,  and  while  these  compounds  can  change  NMDAR  behavior  ex  vivo,  
their  pharmacokinetics  render  them  ill-­suited  to  perform  the  same  function  in  vivo.52  
These  obstacles  necessitate  the  use  of  other  means  in  order  to  rescue  a  more  normal  
glutamatergic  tone.    
   The  metabotropic  glutamate  receptors  (mGluRs,  Fig.  4)  are  class  C  G  protein-­
coupled  receptors  expressed  throughout  the  central  nervous  system.  They  have  large,  
glutamate-­binding  extracellular  domains  called  “Venus  flytrap  domains”  that  are  linked  
to  seven  transmembrane  domains  via  cysteine-­rich  domains.  Upon  ligand  binding,  their  
structure  allows  them  to  transduce  a  signal  across  a  neuronal  cell  membrane  to  mediate  
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intracellular  processes.  As  glutamate  is  the  main  excitatory  neurotransmitter  in  the  CNS,  
the  presence  of  mGluRs  allows  fine-­tuning  of  synaptic  behavior  and  cell  excitability  by  
way  of  second  messenger  signaling  pathways.25  The  mGluRs  are  divided  into  three  
groups  on  the  basis  of  their  amino  acid  sequences  and  the  signaling  pathways  that  they  
Figure  4.  Localization  of  mGluRs  in  a  synapse.  Common  locations  of  mGluRs  at  a  synapse  are  
represented.  mGluRs  contain  characteristic  “venus  flytrap  domains”  on  their  N-­terminus  that  bind  
glutamate,  their  endogenous  ligand.  mGluR2  (purple)  is  found  presynaptically,  and  can  exist  as  a  
heterodimer  with  mGluR4  (red)  or  as  a  homodimer.  mGluR3  (dark  blue)  is  found  both  pre-­  and  
postsynaptically  on  glutamatergic  neurons,  on  glia  (astrocytes),  and  on  modulatory  neurons.    Image  





activate.49  Group  II  is  comprised  of  mGluR2  and  mGluR3.  These  receptors  are  coupled  
to  Gαi/o  G  protein  α  subunits,  and  as  such,  their  signaling  pathway  leads  to  inhibition  of  
adenylate  cyclase,  activation  of  potassium  channels,  and  inhibition  of  voltage-­sensitive  
calcium  channels.26  
     The  group  II  mGluRs  are  situated  around  a  synapse  in  a  particular  fashion  (Fig.  
4).  Both  mGluR2  and  mGluR3  are  found  presynaptically  –  though  not  in  close  proximity  
to  the  active  zone  –  and  can  be  activated  either  by  excess  glutamate  in  the  synapse  or  
by  glutamate  released  from  nearby  astrocytes.53  In  addition  to  presynaptic  neurons,  
mGluR2  and  mGluR3  are  also  found  postsynaptically,  where  mGluR3  in  particular  can  
cause  hyperpolarization.54,55  In  addition  to  these  locales,  mGluR3  is  also  found  on  
astrocytes,  where  it  has  been  shown  to  play  a  critical  role  in  neuroprotective  function.56  
Overall,  both  receptors  are  important  for  inhibition  of  neurotransmitter  release  from  
presynaptic  neurons  as  well  as  for  regulation  of  synaptic  plasticity.25  
   The  first  indications  that  group  II  mGluRs  could  be  targeted  as  a  means  to  rectify  
cortical  glutamatergic  hyperfunction  came  in  1997,  when  scientists  at  Eli  Lilly  &  Co.  
reported  that  the  activation  of  group  II  mGluRs  (via  a  novel  exogenous  agonist  that  they  
synthesized)  could  normalize  excessive  glutamate  release.57-­58  This  compound  was  
LY354740  (Fig.  5a),  a  potent  and  highly  selective  orthosteric  agonist  for  mGluR2/3.  
LY354740  was  quickly  followed  up  by  LY379268  (Fig.  5b),  a  closely-­related  compound  
with  improved  pharmacological  and  pharmacokinetic  properties/characteristics.59  When  
subjected  to  the  NMDAR  antagonism  model,  these  mGluR2/3  agonists  were  able  to  
reduce  and/or  reverse  many  of  the  effects  created  by  NMDAR  blockade,  including  
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hyperlocomotion,  stereotypies,  deficits  in  working  memory,  increased  cortical  glutamate  
efflux,  and  increased  firing  of  PFC  neurons  in  rats.51    
These  beneficial  effects  could  be  blocked  by  the  mGluR2/3  antagonist  LY341495,  
suggesting  that  the  observed  reduction/reversal  of  such  effects  was  mediated  by  the  
mGluR2/3  receptors.60    
   Although  the  prospects  of  LY354740  and  LY379268  were  promising,  their  
development  was  impeded  by  pharmacokinetic  obstacles,  including  low  oral  
bioavailability,  poor  gastrointestinal  tract  absorption,  and  insufficient  CNS  penetrance.13  
The  ensuing  synthesis  of  LY404039  (Fig.  5c)  represented  considerable  improvement  in  
these  areas.  In  rodents,  bioavailability  increased  from  10%  (LY354740)  to  63%  
(LY404039).61  The  compound  maintained  the  qualities  of  its  predecessors  in  terms  of  
potency,  selectivity,  and  putative  antipsychotic  effect.  Moreover,  it  appeared  to  work  
through  a  mechanism  distinct  from  that  of  the  typical  and  atypical  antipsychotics.  
Perhaps  most  encouragingly,  LY404039  1)  did  not  create  any  motor  side  effects  in  
rodents  at  very  high  doses  and  2)  showed  potential  for  efficacy  against  negative  
symptoms  (i.e.  conferring  benefits  for  affective  regulation)13  –  traits  which  are  both  in  





























Figure  5.  Chemical  structures  of  mGluR2/3  agonists.  Structures  of  three  potent  and  highly  
selective  mGluR2/3  agonists,  LY354740  (a),  LY379268  (b),  and  LY404039  (c),  are  shown.  
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of  LY404039  was  lost  to  a  large  degree,  so  Lilly  ultimately  created  the  prodrug  
LY2140023  (pomaglumetad  methionil),  which  has  the  rather  convenient  property  of  
being  a  substrate  for  a  peptide  transporter  in  the  human  gut.  With  this  strategy,  the  
prodrug  is  absorbed  and  then  hydrolyzed,  ultimately  resulting  in  sufficient  concentration  
of  the  active  parent  compound  LY404039  in  the  systemic  circulation.62    
  
2.4:  The  mGluR2/3  Agonist  Pomaglumetad  Methionil  in  Clinical  Trials  
  
   On  the  basis  of  abundant  preclinical  evidence  for  antipsychotic  effect,  Lilly  
advanced  LY2140023  to  human  clinical  trials.  After  establishing  safety  and  tolerability,  
the  first  phase  II  study14  was  initiated.  The  primary  objective  of  this  multicenter,  
randomized,  and  double-­blind  trial  was  to  assess  whether  LY2140023  was  superior  to  
placebo  in  treating  patients  with  schizophrenia  as  measured  by  the  Positive  and  
Negative  Syndrome  Scale  (PANSS  –  as  developed  by  Kay,  Fiszbein,  and  Opler63)  over  
a  28-­day  period.  The  atypical  antipsychotic  olanzapine  was  included  as  an  active  
control.  118  patients  completed  the  28-­day  treatment  period,  with  encouraging  results:  
patients  treated  with  LY2140023  showed  statistically  significant  improvements  in  
both  positive  and  negative  symptoms  of  schizophrenia  compared  to  placebo,  
suggesting  that  LY2140023  might  be  considered  a  broad  spectrum  antipsychotic.  
Treatment  with  LY2140023,  as  well  as  with  olanzapine,  was  generally  safe  and  
well-­tolerated.  Notably,  LY2140023  treatment  did  not  appear  to  be  associated  
with  the  common  dopamine  D2-­related  adverse  events  of  extrapyramidal  motor  
adverse  events,  hyperprolactinemia,  nor  was  it  associated  with  weight  gain.62  
  




   Next,  a  larger  (n  =  669)  phase  II  study15  aimed  at  assessing  efficacy  over  a  larger  
dose  range  of  LY2140023  was  conducted.  Like  the  first  trial,  this  multicenter,  double-­
blind,  and  randomized  trial  measured  primary  outcome  with  the  PANSS,  used  
olanzapine  as  an  active  control,  and  lasted  28  days.  Results  from  this  trial  were  
considered  inconclusive  when  neither  olanzapine  nor  any  dose  of  LY2140023  
separated  from  placebo.  Confusingly,  the  placebo  group  in  this  study  demonstrated  
significant  improvement  as  measured  by  PANSS,  whereas  the  placebo  group  in  the  
earlier  study  showed  no  significant  change.62  
   The  next  trial  sought  to  establish  long-­term  safety,  tolerability,  and  efficacy  of  
LY2140023.  To  do  so,  this  study16  lasted  24  weeks  and  compared  LY2140023  to  the  
current  “standard  of  care”  (SOC)  drugs  olanzapine,  risperidone,  and  aripiprazole.  To  
assess  tolerability,  “discontinuation  due  to  adverse  events”  was  used  as  the  primary  
outcome  measure.  Antipsychotic  efficacy  was  assessed  by  the  PANSS  scale  –  though  it  
is  important  to  note  that  a  placebo  arm  was  not  included.  While  LY2140023  did  not  
create  motor  side  effects  (as  the  SOC  drugs  did),  it  failed  to  achieve  any  long-­term  
efficacy  benefit  over  SOC  drugs  (as  measured  by  PANSS),  which  outperformed  
LY2140023  in  this  regard.62  
   In  2013,  a  smaller  phase  Ib  study17  was  published.  This  trial  had  a  different  
focus:  whether  LY2140023  could  confer  negative  symptom  reduction  when  added  on  
top  of  ongoing  therapy  with  atypical  antipsychotics.  The  results  were  yet  another  blow  to  




In  2014,  results  from  the  largest  trial  ever  conducted  with  LY2140023  were  
published.18  This  phase  II/III  study  randomized  patients  (n  =  1013)  to  one  of  four  
categories:  placebo,  LY2140023  (2  different  doses),  or  risperidone.  The  primary  
outcome  was  measured  by  improvement  in  PANSS  scores  after  six  weeks.  
Unfortunately,  neither  dose  of  LY2140023  separated  from  placebo,  while  risperidone  did  
separate.  In  their  report  on  the  results  of  the  study,  the  authors  concluded:  “further  
understanding  of  the  role  of  glutamate  as  a  therapeutic  target  in  schizophrenia  is  
needed.”18  After  these  repeated  failures,  Eli  Lilly  &  Co.  terminated  the  development  of  
LY2140023.    
  
2.5:  Newer  Insights  on  mGluR2  in  the  Context  of  Schizophrenia  
  
   Over  the  last  ten  years,  numerous  discoveries  concerning  oligomeric  structure,  
behavior,  and  regulation  of  mGluR2  have  been  made.  Many  of  these  findings  have  
immense  functional  relevance  not  only  for  the  receptor  itself,  but  also  to  the  glutamate  
hypothesis  and  to  schizophrenia  in  general.  Furthermore,  these  recent  advances  may  
offer  a  possible  explanation  as  to  why  the  strategy  of  mGluR2/3  agonism  (in  the  form  of  
LY2140023)  failed  to  succeed  in  human  clinical  trials.    
Due  to  the  lack  of  specific  molecular  insight  on  the  causes  of  schizophrenia,  
researchers  have  largely  relied  on  drugs  to  help  guide  their  work.  In  other  words,  
observations  that  certain  drugs  exhibit  antipsychotic  activity  helped  investigators  focus  
on  their  mechanisms  of  action  as  a  way  to  understand  dysfunctional  neurotransmission  
in  the  schizophrenia-­afflicted  brain  (e.g.  chlorpromazine  and  DRD2).  Likewise,  
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observations  that  other  drugs  were  seemingly  pro-­psychotic  (or,  psychotomimetic)  also  
guided  work  in  this  area  (e.g.  PCP  and  NMDAR  hypofunction  leading  to  glutamatergic  
dysfunction  in  the  frontal  cortex).  Thus,  understanding  how  drugs  alleviate  or  create  one  
or  more  symptoms  of  schizophrenia  is  the  primary  way  that  researchers  have  generated  
hypotheses  concerning  dysfunction  of  major  (i.e.  dopamine,  glutamate)  
neurotransmission  systems.  
In  keeping  with  this  conceptual  framework,  clues  from  other  drugs  helped  further  
resolve  the  molecular  interactions  relevant  to  the  mGluR2/3  agonism  treatment  strategy.  
In  addition  to  their  action  at  DRD2,  atypical  antipsychotics  (e.g.  clozapine,  risperidone)  
also  act  as  antagonists  of  the  serotonin  receptor  2A  (5-­HT2AR  or  more  simply  2AR).  Of  
further  relevance  is  the  knowledge  that  hallucinogenic  drugs  such  as  LSD,  DOI,  and  
psilocybin  are  agonists  of  the  2AR  and  cause  changes  in  sensory  processing  and  
perception  –  effects  which  are  blocked  by  atypical  antipsychotics.  So,  while  agonism  of  
mGluR2/3  seems  to  confer  the  desired  effect,  antagonism  of  other  receptors  like  2AR  
achieves  this  as  well.  Though  different  in  their  targets  and  pharmacology,  both  the  
atypical  and  glutamate  antipsychotics  are  alike  in  their  end  result:  antipsychotic  action.  
The  juxtaposition  of  opposing  pharmacological  action  (i.e.  agonism  vs  antagonism)  with  
similar  therapeutic  result  (i.e.  antipsychotic  effect)  begged  the  question:  are  the  2AR  
and  mGluR2/3  related  in  this  context?  In  other  words,  in  the  pathway  from  receptor  
binding  to  eventual  antipsychotic  action,  is  there  a  point  where  their  mechanisms  
converge?    
In  2008,  González-­Maeso  et  al.28  demonstrated  that  the  2AR  and  mGluR2/3  
directly  interact  with  one  another  in  the  form  of  a  heterodimer.  Like  mGluR2/3,  2AR  is  
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also  a  GPCR,  however  it  is  a  member  of  a  different  class  and  has  downstream  signaling  
cascades  distinct  from  those  of  mGluR2/3.  Importantly,  the  interaction  between  the  two  
receptors  was  shown  to  have  functional  consequences.  The  first  suggestion  of  
functional  interplay  came  from  findings  in  mice.  First,  mice  with  a  global  2AR  knockout  
(htr2A–/–)  were  found  to  express  mGluR2  to  a  much  lower  extent  than  wildtype  mice.  
Rescue  of  2AR  expression  reversed  this  phenotype.  Second,  the  mGluR2/3  agonist  
LY379268  increased  the  affinity  of  LSD  and  DOI  for  their  2AR  binding  site.  Conversely,  
the  2AR  agonist  DOI  decreased  the  affinity  of  LY379268  for  its  binding  site  on  
mGluR2/3.  Third,  the  presence  of  specific  downstream  signaling  markers  of  2AR  
activation  by  hallucinogens  was  abolished  by  LY379268.  Lastly,  when  treated  
chronically  with  atypical  antipsychotics,  expression  levels  (mRNA  and  receptor  density)  
of  2AR  and  mGluR2  in  mouse  frontal  cortex  fell  significantly.  Interestingly,  in  the  2AR  
knockouts,  chronic  treatment  with  atypical  antipsychotics  did  not  alter  the  mGluR2  level,  
indicating  that  the  5-­HT2A  receptor  was  necessary  for  the  downregulation  of  mGluR2  by  
this  treatment.28  These  findings  were  congruent  with  studies  showing  different  levels  of  
2AR  and  mGluR2  in  postmortem  human  brains  from  untreated  and  antipsychotic-­
treated  schizophrenia  patients,28  and  thus  further  reiterated  the  functional  implications  of  
the  heterodimeric  complex  in  the  context  of  schizophrenia  and  its  treatment.    
Though  the  2AR  was  known  to  be  required  for  the  downregulatory  effect  of  
chronic  clozapine  treatment  on  mGluR2,  the  specific  mechanism  through  which  this  
proceeded  was  unknown  until  2012,  when  histone  deacetylase  2  (HDAC2)  was  
convincingly  demonstrated  to  be  the  main  effector  in  this  process.  Kurita  et  al.20  showed  
that  chronic  treatment  with  clozapine  causes  a  2AR-­dependent  upregulation  of  HDAC2,  
    
25  
leading  to  increased  HDAC2  binding  to  the  promoter  of  the  mGlu2  gene,  ultimately  
resulting  in  decreased  expression  of  mGluR2  in  both  mouse  and  human  frontal  cortex.  
Concordantly,  adjunctive  treatment  with  the  broad-­spectrum  HDAC  inhibitor  
suberanilohydroxamic  acid  (SAHA)  nullified  this  phenomenon  in  mice,20  in  keeping  with  
clinical  observations  that  HDAC  inhibitors  conferred  additional  antipsychotic  benefit  
when  given  in  conjunction  with  atypical  antipsychotics.64-­66    
More  recently,  HDAC2  has  also  been  implicated  as  a  driver  of  a  number  of  
neurological  side  effects  caused  by  chronic  treatment  with  atypical  antipsychotics,  such  
as  decreases  in  mature  synapse  number.22  Along  the  same  lines,  since  mGluR2  is  
crucially  important  for  the  induction  of  long-­term  depression  in  the  cortex  as  well  as  at  
synapses  between  mossy  fibers  and  hippocampal  CA3,  its  dysregulation  contributes  to  
impairments  in  synaptic  plasticity.67  Thus,  it  is  conceivable  that  the  therapeutic  benefits  
of  chronic  treatment  with  atypical  antipsychotics  may  be  restrained  by  the  negative  
effects  of  the  HDAC2  upregulation  that  these  drugs  induce.  
Finally,  the  downregulation  of  mGluR2  by  atypical  antipsychotics  has  relevance  
to  the  interpretation  of  the  performance  of  LY2140023  in  clinical  trials.  Citing  the  
previously  discussed  2012  work  by  Kurita  et  al.,  investigators  at  Eli  Lilly  gave  due  
consideration  to  this  possibility  in  a  post-­hoc  analysis  of  the  trials,  writing:  
The  possible  epigenetic  influence  of  prior  atypical  anti-­psychotic  treatment  to  
down-­regulate  the  mGlu2  receptor  is  a  phenomenon  that  has  only  recently  been  
demonstrated  in  the  laboratory  and  has  not  yet  been  accommodated  into  
preclinical  models  that  screen  for  potential  new  antipsychotic  medications.  Thus,  
the  well-­characterized  ability  of  pomaglumetad  to  block  the  psychosis-­like  effects  
of  N-­methyl-­D-­aspartate  antagonists,  such  as  phencyclidine  and  ketamine  in  
animals,  may  not  have  translated  to  the  clinic  as  most  patients  in  schizophrenia  
trials  have  in  fact  had  substantial  previous  treatment  exposure  to  atypical  
antipsychotic  drugs  or,  more  specifically,  to  drugs  with  prominent  5-­HT2A  
    
26  
antagonist  attributes  …  It  is  an  intriguing  possibility  that  the  intimate  relationship  
between  5-­HT2A  and  mGlu2  receptors  extend  to  epigenetic  interactions  and  that  
chronic  5-­HT2A  receptor  blockade  might  lead  to  a  down-­regulation  of  mGlu2  
receptor  levels.  Thus,  even  if  a  hyper-­glutamatergic  state  contributes  to  
schizophrenic  symptoms,  a  treatment  targeted  to  mGlu2  receptor  activation  
would  yield  reduced  efficacy  if  the  receptor  target  levels  were  notably  reduced.  
Consistent  with  this  hypothesis,  our  post  hoc  analyses  indicated  that  patients  
with  chronic  exposure  to  agents  containing  potent  5-­HT2A  receptor  antagonism  
exhibited  a  lack  of  therapeutic  response  to  pomaglumetad,  which  suggests  that  
preservation  of  the  mGlu2  receptor  target  is  necessary  to  effect  an  antipsychotic  
response  to  pomaglumetad.23  
  
  
Accordingly,  it  is  possible  that  patient  selection  –  conducted  without  knowledge  and/or  
consideration  of  the  effects  of  chronic  atypical  antipsychotics  on  mGluR2  –  could  be  
responsible  for  at  least  some  of  the  failure  of  LY2140023  to  succeed  in  clinical  trials.  As  
such,  design  of  future  clinical  studies  with  glutamatergic  antipsychotics  should  account  
for  recent  elucidation  of  the  role  of  HDAC2  in  downregulation  of  mGluR2  following  















Chapter  3:  Methods  and  Development  
  
3.1:  Generation  of  HDAC2  Conditional  Knock-­out  Mice  
  
   In  mice,  HDAC2  is  expressed  ubiquitously68,  and  global  deletion  of  widely-­
expressed  Hdac2  results  in  either  embryonic  lethality  or  perinatal  lethality  due  to  
impaired  development  and  a  variety  of  defects.22  Therefore,  another  approach  is  
necessary  to  delete  HDAC2  expression  in  cortical  pyramidal  neurons.  CaMKIIα  is  a  
marker  of  forebrain  glutamatergic  pyramidal  neurons.69  Expression  of  this  marker  in  
these  neurons  begins  10-­14  days  after  birth.70  Therefore,  when  deployed  as  part  of  a  
Cre-­Lox  recombinase  system,  CaMKIIα  can  confer  both  temporal  and  cell  type  
specificity.  To  take  advantage  of  this,  transgenic  C57BL/6  mice  heterozygous  for  
CaMKIIα-­Cre  were  bred  with  mice  homozygous  for  Hdac2loxP/loxP.  Consequently,  
offspring  that  express  Cre  will  delete  Hdac2  in  neurons  expressing  CaMKIIα.  
Conversely,  offspring  that  do  not  express  Cre  will  have  normal  function  of  HDAC2.  This  
approach  bypasses  developmental  impairments  and  abnormalities  associated  with  
global  Hdac2  deletion  and  generates  a  viable  mouse  line  with  conditional  knockout  of  







3.2:  Mouse  Genotyping  
  
   At  weaning  (28  days  
after  birth),  ear  punches  
were  obtained  from  each  
mouse  and  frozen  at  -­80°C.  
To  isolate  DNA,  the  tissue  
was  placed  in  a  PCR  tube  
containing  200µL  GNT-­K  
buffer  (50  mM  KCl,  1.5  mM  
MgCl2,  10  mM  Tris-­HCl,  
0.01%  gelatin,  0.45%  
Igepal®  GA-­630  [Sigma  
I3021],  0.45%  Tween®  20  [Sigma  P1379]  and  100  µg/ml  proteinase  K),  which  was  
incubated  at  55°C  for  2  hours  and  then  heated  at  95°C  for  15  minutes.  For  PCR  
amplification,  22  µL  of  primer  mixture  containing  primers  for  CaMKII-­Cre  (Table  1)  or  
Hdac2loxP/loxP  (Table  2)  each  at  a  concentration  of  100  µM  was  added  to  a  PCR  tube  
containing  a  PuReTaq  Ready-­To-­Go  PCR  Bead  (Amersham  27-­9557-­01),  followed  by  
the  addition  of  3  µL  of  isolated  DNA.  A  representative  photograph  of  DNA  
electrophoresis  gels  corresponding  to  genotyping  results  for  CaMKII-­Cre  and  
Hdac2loxP/loxP  can  be  found  in  Figures  6  and  7,  respectively.    
  
Figure   6.   Representative   results   of  CaMKII-­Cre   genotyping.  
Photograph  of  agarose  gel  indicating  if  young  mice  were  positive  
(+,  black  circles)  or  negative  (-­)  for  the  Cre  transgene  (~100  bp).  
The  band  at  ~324  bp  corresponds  to  the  internal  positive  control.    
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Table  1.  PCR  Primers  and  Protocol  Used  for  CaMKII-­Cre  Genotyping.  
PCR  Primers           
Primer   Primer  Type   Sequence  (5’  à  3’)  
oIMR1084   Transgene   GCG  GTC  TGG  CAG  TAA  AAA  CTA  TC  
oIMR1085   Transgene   GTG  AAA  CAG  CAT  TGC  TGT  CAC  TT  
oIMR7338   Internal  Positive  Control   CTA  GGC  CAC  AGA  ATT  GAA  AGA  TCT  
oIMR7339   Internal  Positive  Control   GTA  GGT  GGA  AAT  TCT  AGC  ATC  ATC  C  
PCR  Protocol           
Step   Temp.  (°C)   Time   Note  
1   94   3  min     
2   94   30  sec     
3   51.7   1  min     
4   72   1  min   Repeat  steps  2-­4  35  times  
5   72   2  min     
6   10   ∞   Final  hold  
  
Table  2.  PCR  Primers  and  Protocol  Used  for  Hdac2loxP/loxP  Genotyping.  
PCR  Primers           
Primer   Primer  Type   Sequence  (5’  à  3’)  
HDAC2  WT  FOR   Reaction  1:  WT  allele   GCA  CAG  GCT  ACT  ACT  GTG  TAG  TCC  
HDAC2  REV   Reaction  1:  WT  allele   CCA  CCA  CTG  ACA  TGT  ACC  CAA  C  
HDAC2  MUT  FOR   Reaction  2:    loxP  allele   GTC  CCT  CGA  CCT  GCA  GGA  ATT  C  
HDAC2  REV   Reaction  2:    loxP  allele   CCA  CCA  CTG  ACA  TGT  ACC  CAA  C  
PCR  Protocol           
Step   Temp.  (°C)   Time   Note  
1   94   2  min     
2   94   15  sec     
3   60   30  sec     
4   72   40  sec   Repeat  steps  2-­4  30  times  
    
30  
5   72   5  min     




3.3:  Chronic  Treatment  of  Mice  
  
Adult  male  and  female  C57BL/6  mice  (10-­20  weeks  old)  were  chronically  treated  
with  daily  intraperitoneal  injection  of  clozapine  
(10  mg/kg  –  obtained  from  Tocris  Cookson  Inc.)  
or  vehicle  for  21  consecutive  days.  Clozapine  
was  dissolved  in  DMSO  supplemented  with  a  
minimal  amount  of  acetic  acid  and  suspended  in  
saline.  24  hours  after  the  final  treatment  was  
administered,  mice  were  sacrificed  by  cervical  
dislocation  immediately  followed  by  decapitation.  
Brains  were  removed,  washed  briefly  in  
phosphate-­buffered  saline  (pH  7.4),  and  
dissected  for  bilateral  frontal  cortex  (bregma  1.90  
to  1.40  mm)  on  an  ice-­cooled  petri  dish  lid.  
Tissue  was  promptly  frozen  in  a  1.5  mL  
microcentrifuge  tube  at  -­80C.  Animals  were  
housed  at  12  h  light/dark  cycle  at  23°C  with  food  and  water  ad  libitum.  Experiments  
were  conducted  in  accord  with  NIH  guidelines,  and  were  approved  by  the  Virginia  
Figure   7.   Representative   results   of  
Hdac2loxP/loxP   genotyping.   Photograph   of  
agarose   gel   indicating   if   young   mice   were  
positive  or  negative   for  wild-­type  Hdac2   (a)  
and  mutant  Hdac2loxp/loxp   (b),  both  ~450  bp.  
All   mice   used   in   the   study   efficiently  
expressed  Hdac2loxp/loxp.  Mice  that  expressed  
the   wild-­type   Hdac2   (not   shown)   were  
excluded  from  the  study.  
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Commonwealth  University  Animal  Care  and  Use  Committee.  All  efforts  were  made  to  
minimize  animal  suffering.  
  
3.4:  Preparation  of  Membranes    
  
   Dissected  brain  tissue  was  frozen  at  -­80°C  for  a  minimum  of  24  hours.  After  
thawing  on  ice,  tissue  was  sheared  with  a  syringe  (23G  needle)  in  assay  buffer  (pH  7.7,  
containing,  in  mM:  20  HEPES,  10  MgCl2,  2  EGTA,  100  NaCl)  and  further  homogenized  
in  a  5  mL  Teflon-­glass  grinder.  The  homogenate  was  centrifuged  at  1,000  x  g  for  10  min  
at  4°C.  Next,  the  supernatant  was  centrifuged  at  40,000  x  g  for  20  min  at  4°C.  The  
resulting  pellet  was  washed  with  fresh  assay  buffer  and  centrifuged  twice  more  at  
40,000  x  g  for  20  min  at  4°C  before  storage  at  -­80°C.  Preparation  of  membranes  from  
HEK293  cells  stably  expressing  mGluR3  was  performed  in  the  same  manner.    
  
3.5:  Development  of  Agonist-­stimulated  [35S]GTPγS  Binding  Assay  
  
   Early  attempts  to  perform  LY379268-­stimulated  [35S]GTPγS  binding  assays  in  
native  tissue  membrane  preparations  were  not  successful.  Puzzlingly,  glutamate-­
stimulated  [35S]GTPγS  binding  was  working  as  expected,  indicating  that  the  issue  most  
likely  had  something  to  do  with  LY379268  and/or  the  mGluR2  receptor.  Early  attempts  
at  this  assay  used  native  tissue  membranes  prepared  according  to  previous  literature.71  
After  quantification  by  the  Bradford  method,  10  µg  of  protein  (i.e.  membranes)  was  
added  to  individual  wells  on  a  96-­well  plate  with  the  following  reaction  conditions:  assay  
buffer  (pH  7.4)  containing  20  mM  HEPES,  3  mM  MgCl2,  100  NaCl,  5  µM  GDP,  0.05  nM  
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[35S]GTPγS  (Perkin-­Elmer),  and  20  µL  of  either  cold  GTPγS  (final  concentration  10  µM  
–  for  assessment  of  non-­specific  binding),  vehicle  (for  assessment  of  basal  binding),  or  
LY379268  (Tocris-­Cookson  Inc.)  at  varying  concentrations  for  a  total  reaction  volume  of  
200  µL.  Components  were  added  to  wells  individually  in  the  following  order:  1)  GDP;;  2)  
assay  buffer;;  3)  either  cold  GTPγS,  vehicle,  or  LY379268;;  4)  [35S]GTPγS;;  and  5)  
membranes.  After  incubation  for  1  hour  at  30°C,  the  reaction  was  stopped  by  filtration  
(FilterMate  Harvester,  Perkin-­Elmer)  with  a  glass  fiber  filter  (Printed  Filtermat  A,  Perkin-­
Elmer)  and  washed  6  times  with  ice-­cold  assay  buffer.  The  glass  filter  was  dried  at  55°C  
for  1h,  soaked  in  
scintillation  liquid  (Betaplate  
Scint,  Perkin-­Elmer),  and  
the  radioactivity  counted  by  
a  Microbeta2  counter  
(Perkin-­Elmer).  In  
troubleshooting  the  many  
failures  with  LY379268,  a  
different  mGluR2/3  agonist,  
LY354740,  was  used.  With  
either  agonist,  the  best  
results  able  to  be  obtained  with  these  conditions  were  unsatisfactory  (Fig.  8)  and  not  
sufficiently  robust  for  analysis  of  chronically  treated  mice.    
   After  studying  the  [35S]GTPγS  assay  in  detail72  and  locating  an  example73  using  
conditions  slightly  different  from  those  most  commonly  encountered  in  the  literature,  I  
Figure   8.   Early   attempt   at   LY354740-­stimulated   [35S]GTPγS  
binding  in  mouse  frontal  cortex.  A  weak  signal  amounting  to  only  
11.8%  over  basal  was  the  best  I  was  able  to  obtain  throughout  all  
of  my  attempts  with  the  older  protocol.  Experiment  was  performed  
in   triplicate.   Error   bars   are   ±   SEM.   Nonlinear   regression   was  
performed  in  GraphPad  Prism  (ver.  6).  
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attempted  to  perform  the  assay  in  a  new  way.  In  addition  to  changing  the  reaction  
conditions  (Table  3),  I  also  developed  a  “master-­mix”-­driven  approach,  where  as  many  
components  as  possible  are  mixed  prior  to  plating,  as  opposed  to  adding  all  the  
components  to  each  well  separately.  This  drastically  reduces  variability  across  
wells/replicates  as  well  as  limiting  opportunities  for  mistakes.  The  first  step  is    
Table   3.   Summary   of   improvements   to   protocol   for   agonist-­stimulated  
[35S]GTPγS  binding  assay  for  mGluR2  in  mouse  frontal  cortex.  
Reaction  Component   Previous  Condition   Change   Improved  Condition  
pH   7.4   ▲   7.7  
HEPES   20  mM  
  
20  mM  
NaCl   100  mM  
  
100  mM  
MgCl2   3  mM   ▲   10  mM  
EGTA   none   +   2  mM  
GDP   5  µM   ▲   30  µM  
[35S]GTPyS   0.05  nM   ▲   0.3  nM  
GDP:[35S]GTPyS   100,000  :  1  
  
100,000  :  1  
Protein/well   10  µg  
  
5-­10  µg  
Incubation   1  hr,  30°C   ▼   45  min,  RT  
  
to  load  the  plate  with  20  µL  of  either  1)  cold  GTPγS  (for  quantification  of  non-­specific  
binding,  final  concentration  10  µM);;  2)  vehicle  (i.e.  whatever  substance  the  agonist  or  
test  compound  is  dissolved  in);;  or  3)  varying  concentrations  of  test  compound.  Next,  
calculations  were  performed  in  order  to  create  a  master  mix  (20  mM  HEPES,  10  mM  
MgCl2,  2  mM  EGTA,  100  mM  NaCl,  30  µM  GDP,  0.3  nM  [35S]GTPγS)  at  90%  of  the  total  
volume  required.  The  remaining  10%  of  the  volume  was  contributed  by  the  addition  of  
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membranes  suspended  in  assay  buffer  at  the  desired  concentration.  Once  membranes  
are  added,  the  mixture  is  plated  immediately:  180  µL  is  added  to  each  well  to  create  a  
reaction  volume  of  200  µL.    As  before,  the  reaction  was  stopped  by  harvesting  the  plate  
through  a  glass  fiber  filter  with  6  washes  of  ice-­cold  assay  buffer,  and  the  radioactivity  
was  counted.  This  new  approach  yielded  very  robust  results  (Fig.  9),  and  worked  well  
with  both  LY379268  (Fig.  9a)  and  LY354740  (Fig.  9b).  This  approach  was  used  for  all  
assays  thereafter.
  
Figure   9.   Improved   [35S]GTPγS   assay   conditions   create   robust   concentration-­response   curves.  
Results   from   agonist-­stimulated   [35S]GTPγS   binding   assays   performed   with   the   mGluR2/3   agonists  
LY379268  (a)  and  LY354740  (b)  in  membranes  from  mouse  frontal  cortex  are  shown.  Parameters  resulting  
from  nonlinear  fit  are  shown  beside  each  curve.  Both  experiments  were  performed  in  triplicate.  Error  bars  
are  ±  SEM.  Nonlinear  regression  was  performed  in  GraphPad  Prism  (ver.  6)  as  described  in  section  3.6.    
    
35  
I  have  since  formalized  a  protocol  for  the  agonist-­stimulated  [35S]GTPγS  binding  assay  
in  native  tissue,  and  have  distributed  it  to  members  of  my  laboratory,  who  have  used  it  
with  success.    
     
3.6:  Data  and  Statistical  Analysis  
  
   Agonist-­stimulated  [35S]GTPγS  binding  data  was  analyzed  by  nonlinear  
regression  performed  by  curve  fitting  software  (GraphPad  Prism,  version  6)  using  the  
parameters  listed  in  Table  4.    
Table  4.  Curve  fitting  parameters  used  throughout  this  study.    
Equation   log  (agonist)  vs.  response  (three  parameters)  
Model   Y  =  Bottom  +  (Top  -­  Bottom)  /  (1+10logEC50-­X)  
Constraints   Hill  slope  constrained  to  1  
  
Fold  changes  were  normalized  to  [35S]GTPγS  binding  in  the  absence  of  the  mGluR2/3  
agonist.  An  extra-­sum-­of-­squares  (F-­test)  was  used  to  determine  statistical  difference  
for  simultaneous  analysis  of  binding  curves  (Fig.  13).  Differences  between  experimental  
conditions  were  assessed  by  two-­way  ANOVA  followed  by  Bonferroni’s  post  hoc  test  
(Table  5).  Area  under  curve  analysis  (Fig.  14)  was  conducted  in  GraphPad  Prism  (ver.  
6)  on  each  individual  curve  for  the  chronic  treatment  experiment  (Fig.  13).  Total  area  








Chapter  4:  Results  
  
4.1:  Validation  of  [35S]GTPγS  Assay  
     
   In  addition  to  reproducibility,  validation  of  the  LY379268-­stimulated  [35S]GTPγS  
binding  assay  required  demonstration  of  the  following:  1)  [35S]GTPγS  binding  is  
concentration-­dependent  as  well  as  saturable  with  respect  to  agonist  (Figs.  9a,  11,  12);;    
Figure   10.   LY379268-­stimulated   [35S]GTPγS   binding   activity   is   blocked   by   the  
mGluR2/3   antagonist   LY341495   and   is   lost   in   mGluR2-­KO  mice.   In   wild   type   mice,  
LY379268  (green  circles)  displayed  concentration-­dependent  [35S]GTPγS  binding,  whereas  
LY379268  in  the  presence  of  10  µM  LY341495  (red  triangles)  did  not.  In  mGluR2-­KO  mice,  
concentration-­dependent   [35S]GTPγS  binding   in  response  to  LY379268  was  not  observed  
(blue  squares).    All  assays  were  performed  in  triplicate  with  membrane  homogenate  derived  
from  either  wild  type  or  mGluR2-­KO  mouse  frontal  cortex.  Error  bars  are  ±  SEM.  Nonlinear  
regression  was  performed  in  GraphPad  Prism  (ver.  6)  as  detailed  in  section  3.6.  
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2)  the  agonist  must  be  blocked  by  the  appropriate  antagonist  (LY341495,  Fig.  10).  Both  
of  these  requirements  were  met.    
  
4.2:  Specificity  Between  mGluR2  and  mGluR3  
  
Specific  pharmacological  study  of  either  mGluR2  or  mGluR3  is  complicated  by  
the  fact  that  their  respective  binding  sites  for  glutamate  are  extremely  similar  –  there  are  
no  currently  available  orthosteric  agonists  that  exhibit  sufficient  selectivity  between  
mGluR2  and  









cell  lines  can  be  
used  to  express  
one  of  the  two  receptors  and  study  it  in  isolation,  investigators  wishing  to  parse  apart  
mGluR2-­  or  mGluR3-­specific  effects  in  an  intact  physiological  system  most  likely  must  
rely  on  knockout  animals.    
Figure  11.  mGluR3  does  not  display  functional  activation  in  the  LY379268-­
stimulated   [35S]GTPγS   binding   assay.   Membranes   from   wild   type   mouse  
frontal   cortex   (green   circles)   displayed   concentration-­dependent   [35S]GTPγS  
binding,  but  membranes  from  mGluR2-­KO  mice,  which  still  express  mGluR3,  did  
not  generate  any  signal  under  the  same  conditions.  Both  assays  were  performed  
in   triplicate.   Error   bars   are   ±   SEM.   Nonlinear   regression   was   performed   in  
GraphPad  Prism  (ver.  6)  as  detailed  in  section  3.6.  
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In  some  early  experiments,  I  used  mGluR2  knockout  mice  (mGluR2-­KO)  in  an  
effort  to  assess  the  relative  contributions  of  mGluR2  and  mGluR3  in  the  context  of  my  
LY379268-­stimulated  [35S]GTPγS  binding  assay  (as  developed  for  mouse  frontal  
cortex).  On  first  attempt,  there  was  no  activity  at  all  in  these  mice  (Fig.  10),  which  was  
surprising  for  a  number  of  reasons.  First,  both  mGluR2  and  mGluR3  are  said  to  be  Gi-­
coupled,  which  is  ideal  for  the  [35S]GTPγS  assay.  Second,  LY379268  possesses  
nanomolar  affinity  at  both  receptors.  Third,  mGluR3  is  thought  to  be  expressed  
throughout  all  cortical  layers  in  the  forebrain.74  With  this  in  mind,  I  tried  again  with  
another  mGluR2-­KO  mouse,  and  obtained  very  similar  results  (Fig.  11).    
After  reading  a  recent  report  stating  that  chloride  acts  as  an  agonist  at  all  Group  
II  and  III  metabotropic  glutamate  receptors  except  mGluR2,75  I  wondered  if  this  might  be  
the  reason  why  I  was  unable  to  see  any  signal.  My  reasoning  was  that  if  chloride  does,  
in  fact,  act  as  an  agonist  at  mGluR3,  then  the  high  amounts  of  chloride  in  the  assay  
buffer  might  already  be  reaching  maximal  effect  at  mGluR3  and  addition  of  further  
agonist  in  the  form  of  LY379268  would  not  produce  any  further  [35S]GTPγS  binding.  The  
simple  removal  of  NaCl  from  the  buffer  dropped  the  total  chloride  anion  concentration  
from  120  mM  (100  mM  NaCl  +  10  mM  MgCl2  =  120  mM  Cl-­)  to  20  mM.  This  change  
seemed  to  marginally  improve  results,  going  from  no  signal  to  a  meager  7%  over  basal  
(data  not  shown).  However,  the  removal  of  sodium  drastically  increases  basal  binding  
and  confounds  results,  limiting  any  conclusions  that  could  be  drawn  from  them.  Both  
sodium  and  magnesium  are  important  in  the  reaction,  so  I  attempted  to  use  other  
sources  for  them  that  did  not  contain  chloride  anion  (i.e.  sodium  gluconate  and  
magnesium  gluconate2)  while  holding  other  assay  conditions  constant.  Under  these  
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conditions,  both  LY379268  and  glutamate  failed  to  produce  any  signal  in  mGluR2-­KO  
frontal  cortex  (data  not  shown).    
Interestingly,  I  do  not  seem  to  be  alone  in  my  issues  with  this  assay  at  mGluR3  in  
native  membrane  preparations.  Despite  [35S]GTPγS  binding  being  well-­characterized  for  
mGluR2  in  native  tissue  membranes,  I  have  been  unable  to  locate  any  literature  reports  
where  this  assay  is  demonstrated  in  native  tissue  membrane  preparations  with  mGluR3  
alone  –  although  it  has  been  demonstrated  in  transfected  cells.  Given  the  widespread  
use  of  this  assay,  commentary  on  this  phenomenon  –  one  that  others  have  likely  
encountered  –  is  scarce.  In  a  2008  study  reporting  on  allosteric  modulators  for  mGluR2  
and  mGluR3,  scientists  at  Merck  addressed  this  problem:    
Despite   finding   [multiple   allosteric  modulators   and   agonists]   to   be   active  …   in  
human  mGluR3  recombinant  membranes  as  well  as  in  transiently  transfected  cells,  
we  did  not  see  biphasic  curves  with   the   rat  brain  membranes.  A   recent  study74  
gives  a  very  detailed  report  on  the  distribution  of  mGluR2  and  mGluR3  in  the  rat  
forebrain.  The  two  receptors  seem  to  be   fairly  evenly  distributed   throughout   the  
forebrain,   suggesting   that   making   large-­scale   membrane   preparations   from  
specific  brain  regions  to  favor  mGluR2  or  mGluR3  would  be  very  difficult.  However,  
it  would  seem  from  their  study  that  sufficient  levels  of  mGluR3  should  have  been  
present   in   the  membranes  prepared   from   rat  whole   brain   to   see  an  agonist   or  
allosteric  modulator  response.  Our  recombinant  mGluR3  membranes  had  an  EC50  
value  of  just  >100  nM  (data  not  shown),  and  it  is  difficult  to  remove  endogenous  
glutamate   in   the  rat  brain  preparations   to   levels  below  1  µM  to  use   for  mGluR2  
testing.  It  is  likely  that  residual  glutamate  was  already  near  the  mGluR3  Emax  value  
before  the  addition  of  glutamate.  Therefore,  at  the  1  µM  concentration  of  glutamate  
we  used   in   the  assay,   the  native  rat  brain  mGluR3  would   likely  have  been  fully  
activated   by   residual   glutamate.   Any   additional  mGluR3   activity   caused   by   the  
compounds  would  be  above  the  100%  glutamate  response  (i.e.,  from  100  to  110%)  
…   Attempts   to   further   remove   the   residual   glutamate   from   the   rat   brain  
preparations  resulted  in  increasing  loss  of  activity.76  
  
  
If  retention  of  endogenous  glutamate  in  membrane  preparations  is,  in  fact,  the  source  of  
the  issue,  I  reasoned  that  I  should  be  able  to  use  the  orthosteric  mGluR2/3  antagonist  
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LY341495  in  increasing  concentration  to  compete  with  the  retained  endogenous  
glutamate  and  decrease  the  level  of  basal  [35S]GTPγS  binding.  However,  the  potent  
antagonist  had  no  effect  at  concentrations  up  to  and  including  1  µM  in  native  membrane  
preparations  from  the  frontal  cortex  of  mGluR2-­KO  mice  (data  not  shown).  
   At  this  point,  it  began  to  seem  as  though  the  assay,  as  performed,  was  specific  
for  mGluR2.  To  test  this,  I  performed  a  LY379268-­stimulated  [35S]GTPγS  binding  
experiment  in  wild  type  mice  where  half  of  the  replicates  also  contained  ML  337,  a  
  
Figure  12.  LY379268-­stimulated  [35S]GTPγS  binding  in  wild  type  mouse  frontal  cortex  is  unaffected  
by   ML   337.   There   was   no   significant   difference   between   LY379268-­stimulated   binding   (black)   and  
LY379268-­stimulated  binding  in  the  presence  of  the  mGluR3-­selective  NAM  ML  337  (orange).  Both  assays  
were  performed  in  triplicate.  Error  bars  are  ±  SEM.  Nonlinear  regression  was  performed  in  GraphPad  Prism  
(ver.  6)  as  detailed  in  section  3.6.  
  
selective  negative  allosteric  modulator  (NAM)  of  mGluR3,  at  a  concentration  of  10  µM.  If  
mGluR3  was  contributing  to  the  overall  signal  from  LY379268  in  mice  containing  
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mGluR2  and  mGluR3,  then  the  presence  of  the  mGluR3  NAM  should  decrease  
[35S]GTPγS  binding  in  some  amount  dependent  on  what  relative  proportion  of  the  
overall  signal  was  due  to  mGluR3.  Results  of  this  experiment  showed  that  mGluR3  is  
not  contributing  to  the  overall  signal  in  any  significant  manner  (Fig.  12),  lending  further  
support  to  the  idea  of  an  mGluR2-­specific  assay.  
Due  to  the  limited  amount  of  mice  available,  another  system  in  which  to  conduct  
further  investigation  into  the  nature  of  mGluR3  in  agonist-­stimulated  [35S]GTPγS  binding  
was  necessary.  I  shifted  my  focus  to  HEK293  cells  stably  expressing  mGluR3  cells  in  
an  attempt  to  see  if  I  could  identify  conditions  that  might  translate  into  success  in  native  
tissue  membranes.  The  best  results  that  could  be  obtained  were  13%  over  basal  (data  
not  shown),  which  is  still  undesirably  low.  Although  I  cannot  offer  an  explanation  as  to  
why  mGluR3  does  not  generate  signal  in  native  tissue  membranes,  in  light  of  these  
findings  overall  it  seems  that  the  [35S]GTPγS  binding  assay,  at  least  as  performed  in  
native  membranes  with  the  conditions  present  in  this  study,  is  specific  to  mGluR2  
despite  the  use  of  the  mGluR2/3  agonist  LY379268.  
  
4.3:  Effect  of  Chronic  Clozapine  on  mGluR2  G  Protein  Coupling  
  
   Considering  the  well-­established  downregulation  of  mGluR2  following  chronic  
exposure  to  atypical  antipsychotics,  I  hypothesized  that  chronic  treatment  with  
clozapine,  via  an  HDAC2-­mediated  mechanism,  would  reduce  functional  activation  of  
mGluR2  at  the  level  of  its  G  protein  (i.e.  reduced  G  protein  coupling).  In  order  to  test  
this,  the  mGlu2/3  receptor  agonist  LY379268  was  used  to  perform  a  series  of  agonist-­
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stimulated  [35S]GTPγS  binding  assays  in  frontal  cortex  membrane  preparations  from  
control  and  HDAC2-­cKO  mice.  In  
untreated  wild-­type  mice  used  to  
confirm  validity  of  the  assay  before  
proceeding  with  chronic  treatment,  
LY379268  induced  binding  of  the  
hydrolysis-­resistant  [35S]GTPγS  to  
the  Gα  subunit  coupled  to  mGluR2  
in  a  concentration-­dependent  
fashion,  and  was  blocked  by  the  
mGluR2/3  antagonist  LY341495.    
For  the  chronic  treatment  
mice,  the  LY379268-­stimulated  
binding  assays  generated  
concentration-­response  data  for  
each  mouse,  which  was  analyzed  by  
nonlinear  regression  to  build  
concentration-­response  curves  and  
derive  pharmacological  parameters  
such  as  potency  (EC50)  and  efficacy  
(Emax).  As  expected,  control  mice  
chronically  treated  with  clozapine  
showed  concentration-­response  relationships  significantly  different  from  control  mice  
Figure  13.  Chronic  clozapine  decreases  LY379268-­
stimulated  [35S]GTPγS  binding  in  the  frontal  cortex  
of   control   mice,   an   effect   that   is   lost   in   HDAC2-­
cKOs.   Shown   above   are   concentration-­response  
curves   depicting   LY379268-­stimulated   [35S]GTPγS  
binding   in   native   tissue   membrane   preparations   of  
frontal  cortex  from  control  mice  (a)  and  HDAC2-­cKO  (b)  
chronically   treated   with   either   clozapine   or   vehicle  
(saline).   All   mice   were   treated   once   daily   with  
intraperitoneal  injections  of  either  clozapine  (10  mg/kg)  
or  vehicle  for  21  consecutive  days.  Mice  were  sacrificed  
24   hours   after   the   final   injection   (n   =   12   mice   per  
experimental  condition).  Least  squares  F-­test  (n.s.,  not  
significant;;  ***P<0.001).  See  also  Fig.  14  and  Table  5.  
    
43  
chronically  treated  with  saline  (Fig.  13a)  (least  squares  F-­test,  F(3,154)=18,63,  P  <  
0.0001).  Specifically,  in  control  mice  chronically  treated  with  clozapine,  both  the  efficacy  
and  potency  of  LY379268  were  significantly  decreased  (Fig.  13a  and  Table  5).  As  
expected,  however,  these  effects  were  not  observed  in  the  HDAC2-­cKO  mice  (Fig.  13b  
and  Table  5)  (Emax,  two-­way  ANOVA;;  genotype  effect,  F(1,44)=67.41,  P<0.0001;;  
treatment  effect,  F(1,44)=1.85,  P>0.05;;  post  hoc:  controls  (clozapine  vs.  vehicle)  
P=0.030;;  HDAC2-­cKOs  (clozapine  vs.  vehicle)  P>0.05)  (EC50,  two-­way  ANOVA;;  
genotype  effect,  F(1,44)=3.415,  P=0.071;;  treatment  effect,  F(1,44)=12.24,  P=0.001;;  
post  hoc:  controls  (clozapine  vs.  vehicle)  P=0.003;;  HDAC2-­cKOs  (clozapine  vs.  vehicle)  
P>0.05).  Area  under  curve  analysis  (Fig.  14)  provides  another  way  of  visualizing  the  
data  presented  in  Figure  13  and  Table  5.    
Table   5.   Pharmacological   parameters   relative   to   LY379268-­induced  
[35S]GTPγS  binding  in  frontal  cortex  membrane  preparations  from  control  and  
HDAC2-­cKO  mice  previously  treated  with  chronic  clozapine  or  vehicle.  
          
 Chronic  Vehicle  
   Chronic  Clozapine  
  
n   Emax  (fold-­over  basal  ±  SEM)  
EC50      n   Emax  (fold-­over  basal  ±  SEM)  
EC50  
   (logM  ±  SEM)   (logM  ±  SEM)  
Cre  -­   12   1.557  ±  0.028   -­7.733  ±  0.097        12   1.475  ±  0.022a   -­7.357  ±  0.083b  
HDAC2-­
cKOs   12   1.663  ±  0.014   -­7.475  ±  0.039        12   1.691  ±  0.008   -­7.353  ±  0.049  
a  There  is  a  significant  difference  (P<  0.05)  in  Emax  between  the  Cre  -­  mice  treated  with  vehicle  and  
the  Cre  -­  mice  treated  with  clozapine.  b  There  is  a  significant  difference  (P<  0.01)  in  EC50  between  
the  Cre  -­  mice  treated  with  vehicle  and  the  Cre  -­  mice  treated  with  clozapine.  A  two-­way  ANOVA  
with  Bonferroni's  post  hoc  test  was  used  for  statistical  comparison.  
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Figure  14.  Total  area  under  curve  for  each  experimental  condition.  Total  area  under  curve  was  
computed  for  each  individual  curve  in  each  experimental  group  (n=12  curves  per  group)  in  Prism  
(ver.   6)   as   detailed   in   section   3.6.  There  was   a   significant   difference   in   total   area   under   curve  
between  the  Cre  -­  mice  treated  with  vehicle  and  the  Cre  -­  mice  treated  with  clozapine  which  was  
not  observed  when  comparing  the  Cre  -­  mice  treated  with  vehicle  and  the  two  other  groups  (two-­





Chapter  5:  Discussion  
  
   The  mechanism  by  which  chronic  clozapine  treatment  upregulates  HDAC2  
expression  and  thus  causes  downstream  epigenetic  modifications  has  very  recently  
been  further  characterized  by  Ibi  et  al.22  Decreased  signaling  from  the  5-­HT2A  receptor  
diminishes  one  of  the  roles  of  this  receptor:  activation  of  the  MAPK-­ERK  signaling  
pathway.  This  results  in  downregulation  of  IκBα,  which  has  the  successive  effect  of  
increasing  nuclear  translocation  of  NF-­κB.  Inside  the  nucleus,  it  binds  to  the  promoter  of  
Hdac2,  upregulating  its  expression.  The  authors  state  that  the  repressive  changes  
caused  by  increased  HDAC2  ultimately  results  in  a  lower  number  of  mature  synapses,  
decreased  synaptic  plasticity,  and  impaired  cognitive  processing.22  Consistent  with  this  
report,  my  results  support  the  critical  role  of  HDAC2  in  epigenetic  changes  caused  by  
chronic  exposure  to  atypical  antipsychotics.  However,  my  findings  are  largely  situated  
just  beyond  where  the  authors’  mechanism  ends.  In  showing  that  chronic  treatment  with  
clozapine  decreases  G  protein  coupling  of  mGluR2,  I  illuminate  a  specific  functional  
outcome  that  has  relevance  to  treatment  of  schizophrenia.  
   In  neurons,  the  opposing  processes  of  long-­term  potentiation  and  long-­term  
depression  (LTD)  are  critical  for  the  plasticity  of  synapses.  This  is  especially  important  
in  the  PFC,  where  dysfunction  (e.g.  in  mental  disorders  like  schizophrenia)  creates  
deficits  in  cognition.  On  a  fundamental  level,  neurons  in  the  cortex  rely  on  dynamic  
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regulation  of  the  balance  between  excitation  and  inhibition  in  order  to  function  properly.  
When  tight  control  of  this  balance  is  lost,  synapses  display  dysfunctional  behaviors.77  
For  instance,  schizophrenia  is  marked  by  improper  glutamatergic  activity  in  the  PFC,  
leading  to  a  host  of  issues  including  abnormal  sensory  perception.  Given  the  role  of  
mGluR2  in  synaptic  LTD,  when  this  receptor  behaves  aberrantly,  there  is  a  diminished  
ability  of  neurons  to  de-­potentiate  synapses,  contributing  to  a  loss  of  synaptic  plasticity.  
In  other  words,  one  of  the  brain’s  means  of  controlling  the  balance  of  excitation  and  
inhibition  is  disrupted.  In  this  way,  it  is  conceivable  that  loss  of  normal  functional  
activation  of  mGluR2  contributes  to  cognitive  impairments  that  long-­term  antipsychotic  
drugs  commonly  exacerbate.    
   Throughout  the  development  and  optimization  of  the  LY379268-­stimulated  
[35S]GTPγS  binding  assay,  questions  surrounding  the  apparent  lack  of  contribution  by  
mGluR3  to  the  overall  signal  produced  by  an  mGluR2/3  agonist  began  to  emerge.  While  
I  am  unable  to  offer  an  explanation  as  to  why  this  Gi-­coupled  receptor  does  not  produce  
robust  signals  in  native  tissue  membrane  preparations,  my  results  (Figs.  10,  11,  12,  as  
well  as  with  LY341495  in  mGluR2KO  mice)  lead  me  to  believe  that  the  [35S]GTPγS  
assay,  at  least  as  performed  in  native  frontal  cortex  membrane  preparations  as  
described  here,  is  specific  for  mGluR2.  Thus,  conclusions  from  the  chronic  treatment  
experiment  (Fig.  13)  apply  to  mGluR2,  but  not  mGluR3.    
It  seems  that  a  main  target  of  the  newer  glutamatergic  antipsychotics  (mGluR2)  
is  rendered  less  available  and  less  functional  by  chronic  treatment  with  current  SOC  
atypical  antipsychotics  like  clozapine.  The  unfortunate  corollary  of  this  phenomenon  is  
that  newer  drugs  being  developed  (i.e.  mGluR2/3  agonists)  may  not  work  for  those  who  
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are  in  the  most  need  for  new  treatments  (i.e.  patients  with  treatment-­resistant  
schizophrenia),  since  clozapine  is  the  only  drug  approved  to  treat  this  population.  This  
has  relevance  to  interpretation  of  clinical  trials,  as  previously  discussed.  However,  
emerging  knowledge  about  how  HDAC2  causes  these  changes  is  useful  in  the  ongoing  
quest  to  develop  new  and  effective  treatments.  For  example,  might  HDAC  inhibition  in  
conjunction  with  pomaglumetad  be  a  viable  strategy  for  patients  who  would  not  
otherwise  respond?  Similarly,  could  HDAC  inhibition  in  conjunction  with  clozapine  help  
attenuate  the  HDAC2  upregulation  that,  in  rodent  models,  has  repeatedly  been  shown  
to  create  cognitive  deficits,  and  may  also  be  responsible  for  the  same  effects  seen  in  
humans?  The  drugs  that  are  currently  approved  to  treat  schizophrenia  have  not  evolved  
much  in  multiple  decades  despite  many  problems  with  efficacy  and  side  effects,  
presumably  owing  to  the  difficulty  in  identifying  viable  molecular  targets.  Perhaps,  with  
the  knowledge  of  the  role  of  HDAC2,  we  may  have  identified  a  new  molecular  target  
whose  manipulation  might  represent  a  new  avenue  to  improve  the  treatment  scenario  
for  the  millions  of  people  who  suffer  from  schizophrenia  worldwide.  
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